Genetic Testing for Disease: How Signal-Based Medicine Reads Your Biological Blueprint
Your doctor orders genetic testing. Results come back normal. Yet you still wake exhausted, think through brain fog, and live with pain no specialist can explain. Standard genetic testing asks the wrong question: it screens for mutations that cause disease, not the biological processes failing right now. KureBioMap™ Signal System Mapping evaluates 183 genes across 15 metabolic pathways to identify why your cells cannot produce energy, clear toxins, or repair damage—the upstream dysfunction conventional labs never measure.
The distinction matters clinically. A standard genetic test ordered through your primary care physician screens for high-penetrance mutations: BRCA1/BRCA2 for breast cancer, Factor V Leiden for clotting disorders, familial hypercholesterolemia variants. These tests answer a binary question: do you carry a mutation that will likely cause disease? KureBioMap™ answers a different question: which biological signals are your genes producing right now, and how are those signals creating the symptoms you experience?
Dr. Peter F. Demitry, MD — a retired Air Force Colonel who served as Assistant Air Force Surgeon General for Modernization — brings a military medicine background where readiness depends on identifying physiological problems before they become disqualifying. The same upstream principle translates directly to civilian medicine: genetic information becomes clinically actionable when it identifies modifiable biological processes, not just inherited risk.
What Genetic Testing for Disease Actually Measures
Genetic testing for disease falls into three clinical categories, each serving a distinct diagnostic purpose.
Diagnostic genetic testing confirms a suspected genetic condition when symptoms are already present. A clinician orders this test when clinical presentation suggests a specific genetic disorder—whole exome sequencing for a child with unexplained developmental delays, or CFTR gene analysis for someone with chronic respiratory infections and malabsorption. These tests provide a definitive molecular diagnosis that changes treatment strategy.
Predictive genetic testing identifies mutations that increase disease risk in asymptomatic individuals. BRCA testing in women with strong family history of breast cancer. Lynch syndrome screening in families with early-onset colorectal cancer. Huntington disease testing in at-risk individuals. The clinical utility depends on whether effective prevention or early intervention exists. Knowing you carry a BRCA mutation allows prophylactic mastectomy or intensive surveillance. Knowing you carry Huntington disease provides reproductive planning information but no disease-modifying intervention.
Pharmacogenomic testing reveals how your genes affect drug metabolism. CYP2C19 variants predict clopidogrel response after cardiac stent placement. CYP2D6 variants determine whether codeine produces effective analgesia or toxic metabolite accumulation. TPMT variants guide thiopurine dosing in inflammatory bowel disease. This testing prevents adverse drug reactions and identifies patients who need alternative medications or dose adjustments.
KureBioMap™ operates in a fourth category: signal system mapping. Standard genetic testing asks whether you carry a mutation that causes disease. KureBioMap™ asks which biological processes are failing right now based on how your genes express under current environmental conditions. We assess 183 genes regulating cellular energy production, mitochondrial function, methylation capacity, glutathione synthesis, inflammatory signaling, and hormone metabolism. These are not disease genes—they are function genes. The clinical question is not whether you will develop a genetic condition. The clinical question is why you experience fatigue, brain fog, chronic pain, or treatment-resistant symptoms when conventional labs show nothing wrong. KureBioMap™ identifies the upstream metabolic dysfunction standard genetic testing never evaluates.
How KureBioMap™ Identifies Upstream Dysfunction
KureBioMap™ Signal System Mapping evaluates 183 genes organized into 15 functional pathways. Each pathway represents a biological system that conventional lab work measures only after it fails.
The methylation pathway includes MTHFR C677T and A1298C variants, MTR and MTRR genes regulating B12 activation, and COMT variants affecting neurotransmitter breakdown. Members with combined MTHFR 677 homozygosity and COMT Met/Met variants accumulate homocysteine, produce insufficient SAMe for cellular methylation reactions, and clear catecholamines slowly. Clinical presentation includes anxiety, insomnia, elevated cardiovascular risk markers, and poor response to standard antidepressants. Standard psychiatric evaluation identifies generalized anxiety disorder and prescribes SSRIs. KureBioMap™ identifies the methylation bottleneck and prescribes methylated B vitamins, SAMe, and magnesium glycinate—addressing the upstream signal rather than suppressing downstream symptoms.
The detoxification pathway evaluates Phase I enzymes (CYP1A1, CYP1B1, CYP2D6, CYP3A4) and Phase II conjugation genes (GST family, NAT2, UGT1A1). A member with slow CYP1A1 and fast CYP1B1 produces excess 4-hydroxyestrone, a genotoxic estrogen metabolite linked to breast cancer risk. Conventional hormone panels show normal estradiol levels. Estrogen metabolite testing through KureBioMap™ reveals the 2-hydroxyestrone to 4-hydroxyestrone ratio is 0.4 (optimal is above 2.0). The intervention: DIM supplementation, cruciferous vegetable intake, and reduced xenoestrogen exposure shift metabolism toward protective pathways.
The inflammatory response pathway includes TNF-alpha, IL-6, IL-1beta, and NF-kappa-B regulatory genes. Members with IL-6 -174 GG genotype produce 2-3 times baseline IL-6 in response to inflammatory triggers. This manifests as treatment-resistant joint pain, prolonged recovery from injury, and elevated hsCRP despite normal lifestyle. Anti-inflammatory medications provide temporary relief without addressing signal amplification. KureBioMap™ identifies the genetic inflammatory amplification and prescribes omega-3 fatty acids at therapeutic dose (2-4 grams EPA/DHA daily), curcumin with piperine for NF-kappa-B inhibition, and elimination of dietary inflammatory triggers.
Jeffrey Bland, PhD, founder of the Institute for Functional Medicine, established that nutrigenomic intervention targeting NF-kappa-B reduces inflammatory marker expression by 40-60% in genetically predisposed individuals when dietary modification and targeted supplementation address the upstream signal rather than suppressing the downstream inflammatory cascade with pharmaceuticals.
The mitochondrial function pathway evaluates genes controlling ATP production, oxidative phosphorylation, and antioxidant defense. SOD2 variants reduce superoxide dismutase activity, allowing reactive oxygen species to damage mitochondrial DNA. Members with SOD2 Ala/Ala genotype experience chronic fatigue, exercise intolerance, and brain fog that standard thyroid and iron panels do not explain. KureBioMap™ identifies the mitochondrial oxidative stress vulnerability and prescribes CoQ10, alpha-lipoic acid, N-acetylcysteine, and mitochondrial-supportive B vitamins.
The INFORM Diagnostic Protocol: Sequencing Genetic Data with Functional Assessment
Genetic data becomes clinically actionable when integrated with functional biomarkers, not interpreted in isolation. Kure Health uses the INFORM diagnostic protocol to sequence genetic testing within a structured assessment framework.
INFORM stands for: Intake health timeline, Nutrigenomic analysis, Functional biomarker panel, Organ system evaluation, Root cause identification, Mechanism-targeted intervention.
Intake health timeline documents childhood health events, environmental exposures, medication history, symptom onset patterns, and prior interventions. A member reports chronic sinus infections treated with 15 courses of antibiotics between ages 5 and 15, followed by adult-onset irritable bowel syndrome, seasonal allergies, and Hashimoto thyroiditis at age 32. The timeline reveals antibiotic-induced microbiome disruption as the upstream event preceding immune dysregulation and autoimmune disease.
Nutrigenomic analysis through KureBioMap™ identifies genetic vulnerabilities in detoxification, methylation, inflammation, and gut barrier function. The same member shows HLA-DQ2 haplotype (gluten sensitivity genetic marker), IL-6 -174 GG (inflammatory amplification), and FUT2 non-secretor status (altered gut microbiome composition and increased infection susceptibility).
Functional biomarker panels measure current biological function across systems conventional labs do not assess. For this member: targeted thyroid panel including reverse T3 and thyroid antibodies, 4-point salivary cortisol, HOMA-IR for insulin resistance, vitamin D, homocysteine, omega-3 index, and hsCRP. Results show elevated TPO antibodies at 450 IU/mL (reference range below 35), reverse T3 at 28 ng/dL suppressing thyroid conversion, morning cortisol at 28 nmol/L (indicating HPA axis dysregulation), and HOMA-IR at 2.8 (insulin resistance threshold is 1.5).
Organ system evaluation focuses on gut health as the primary signal block. KureBiome™ uses zonulin measurement and lactulose-mannitol testing to quantify intestinal permeability. Dr. Alessio Fasano, Director of the Center for Celiac Research and Treatment at Massachusetts General Hospital, discovered zonulin as the molecular regulator of intestinal tight junctions. Elevated zonulin above 50 ng/mL indicates active tight junction disassembly and intestinal permeability. This member's zonulin measured 107 ng/mL. Lactulose-mannitol ratio was 0.08 (normal is below 0.03), confirming increased intestinal permeability.
Root cause identification synthesizes genetic predisposition, timeline events, and functional data into a primary signal block. For this member: antibiotic-induced microbiome disruption in childhood created intestinal permeability in a genetically susceptible individual (HLA-DQ2, FUT2 non-secretor, IL-6 inflammatory amplification). Chronic low-grade endotoxemia from bacterial translocation across the permeable gut barrier activated immune dysregulation, eventually targeting thyroid tissue in a genetically predisposed individual.
Mechanism-targeted intervention addresses the primary signal block and downstream consequences simultaneously. Gut barrier restoration: L-glutamine 5 grams twice daily, zinc carnosine, omega-3 fatty acids, and elimination of gluten and dairy for 90 days. Microbiome restoration: multi-strain probiotic with Lactobacillus rhamnosus GG and Bifidobacterium longum, prebiotic fiber, and fermented foods. Thyroid support: selenium 200 mcg daily to reduce TPO antibodies, optimized levothyroxine dosing based on free T3 and reverse T3 levels. Inflammatory modulation: curcumin, omega-3 at therapeutic dose, and blood sugar stabilization to reduce HOMA-IR below 1.5.
Genetic Testing Limitations Conventional Medicine Does Not Explain
Genetic testing for disease carries clinical limitations that marketing materials understate and conventional ordering physicians rarely explain.
Variants of uncertain significance (VUS) appear in 40-50% of clinical exome sequencing results. A VUS is a genetic change that has been identified but lacks sufficient evidence to classify as pathogenic or benign. Your test report states you carry a VUS in the ATM gene associated with cancer risk. This provides zero actionable information. You do not know if this variant increases risk, decreases risk, or has no effect. Surveillance recommendations remain unchanged. The VUS creates anxiety without clinical utility.
Penetrance variability means carrying a disease-associated mutation does not guarantee disease development. BRCA1 mutations carry 55-65% lifetime breast cancer risk, not 100%. APOE e4/e4 genotype increases Alzheimer risk 12-fold but many e4/e4 carriers never develop dementia. Environmental factors, epigenetic modifications, and other genetic variants modulate penetrance. A positive genetic test for increased disease risk is a probability statement, not a certain outcome.
Polygenic conditions involve hundreds of genetic variants, each contributing small effect sizes. Type 2 diabetes, coronary artery disease, hypertension, and most psychiatric conditions are polygenic. Single-gene testing provides incomplete risk assessment. Polygenic risk scores aggregate multiple variants into a composite risk estimate, but these scores explain only 10-30% of disease heritability for most conditions. The remaining risk comes from gene-environment interactions that genetic testing does not capture.
Epigenetic regulation determines whether genes are expressed or silenced based on environmental inputs: diet, stress, toxin exposure, sleep, exercise. Your DNA sequence remains constant, but gene expression changes continuously. Carrying a genetic variant for increased inflammatory response matters clinically only if that gene is actively expressed. KureBioMap™ interpretation accounts for epigenetic modulation by integrating genetic data with functional biomarkers that reflect current gene expression, not just inherited sequence.
Mark Hyman, MD, Head of Strategy at the Cleveland Clinic Center for Functional Medicine, documented that 67% of patients with genetic predisposition to type 2 diabetes prevented disease onset through dietary intervention targeting insulin signaling pathways, demonstrating that genetic risk is modifiable when upstream biological signals are addressed before irreversible metabolic damage occurs.
When Genetic Testing Changes Clinical Decision-Making
Genetic testing for disease provides clinical value when results alter prevention strategy, treatment selection, or family planning decisions.
Cancer predisposition syndromes justify intensive surveillance or prophylactic surgery. A 35-year-old woman with BRCA1 mutation faces 55-65% lifetime breast cancer risk and 39-44% ovarian cancer risk. Prophylactic bilateral mastectomy reduces breast cancer risk by 90%. Prophylactic bilateral salpingo-oophorectomy reduces ovarian cancer risk by 80-90%. Annual breast MRI starting at age 25 detects cancers at earlier stages when treatment is more effective. The genetic test result directly changes medical management in a way that reduces mortality.
Cardiac channelopathies require activity modification and medication to prevent sudden death. Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia are inherited arrhythmia conditions that cause sudden cardiac death in young, otherwise healthy individuals. Genetic testing identifies at-risk family members before symptoms occur. Interventions include beta-blockers, implantable cardioverter-defibrillators, and avoidance of QT-prolonging medications and strenuous exercise. Genetic diagnosis prevents sudden death in asymptomatic carriers.
Pharmacogenomic testing prevents adverse drug reactions and treatment failure. CYP2C19 poor metabolizers prescribed clopidogrel after cardiac stent placement have 3-fold higher risk of stent thrombosis because they cannot convert clopidogrel to its active metabolite. Genetic testing identifies poor metabolizers who require alternative antiplatelet therapy with ticagrelor or prasugrel. CYP2D6 ultrarapid metabolizers convert codeine to morphine excessively, causing respiratory depression and death, particularly in children. Genetic testing prevents codeine prescription in ultrarapid metabolizers.
Reproductive decision-making changes when both partners carry recessive disease mutations. Cystic fibrosis, sickle cell disease, Tay-Sachs disease, and spinal muscular atrophy follow autosomal recessive inheritance. If both parents carry one mutation, each pregnancy has 25% risk of affected offspring. Carrier screening before conception allows informed reproductive choices: preimplantation genetic diagnosis with IVF, prenatal diagnosis with chorionic villus sampling or amniocentesis, use of donor gametes, or adoption.
FAQ: Genetic Testing for Disease
What is the difference between genetic testing and genomic testing?
Genetic testing examines specific genes or chromosomes for known mutations associated with inherited conditions. Genomic testing analyzes large portions of the genome or the entire genome to identify variants across multiple genes and regulatory regions. Genetic testing answers targeted questions about specific conditions. Genomic testing provides broader assessment of biological function and disease risk across multiple systems.
Does insurance cover genetic testing for disease?
Insurance coverage depends on clinical indication and medical necessity criteria. Genetic testing for cancer predisposition syndromes in individuals with strong family history is typically covered. Carrier screening for reproductive planning is often covered. Pharmacogenomic testing is inconsistently covered. Genomic testing for general health optimization or disease prevention in asymptomatic individuals without family history is rarely covered. KureBioMap™ is a cash-pay service because insurance does not reimburse preventive genomic assessment.
Can genetic testing predict all conditions I might develop?
No. Genetic testing identifies inherited risk factors, not destiny. Most common conditions are multifactorial, involving genetic predisposition, environmental exposures, lifestyle factors, and epigenetic modifications. Genetic testing reveals vulnerabilities that increase probability when environmental triggers are present. It does not predict occurrence with certainty. Type 2 diabetes, heart disease, Alzheimer disease, and autoimmune conditions have genetic components, but environmental modification can prevent or delay onset even in genetically predisposed individuals.
What should I do if my genetic test shows increased disease risk?
Increased genetic risk requires mechanism-targeted intervention, not fatalistic acceptance. Identify which biological pathways your genetic variants affect. Measure functional biomarkers that reflect current pathway function. Implement environmental modifications that support vulnerable pathways: nutrient supplementation for methylation defects, anti-inflammatory diet for inflammatory gene variants, mitochondrial support for energy production variants, gut barrier restoration for immune dysregulation risk. Genetic risk becomes clinically actionable when translated into specific biological mechanisms with modifiable interventions.
How is KureBioMap™ different from 23andMe or AncestryDNA?
Direct-to-consumer genetic tests like 23andMe and AncestryDNA provide ancestry information and limited health risk reports based on genome-wide association study data. These tests identify common variants associated with disease risk in population studies but do not provide clinical interpretation or intervention protocols. KureBioMap™ evaluates 183 genes across 15 metabolic pathways with clinical interpretation by functional medicine practitioners. Results are integrated with targeted functional biomarker testing, health timeline analysis, and mechanism-targeted treatment protocols. KureBioMap™ is a clinical diagnostic tool, not a consumer curiosity product.
Will my genetic information be shared with insurance companies or employers?
The Genetic Information Nondiscrimination Act (GINA) prohibits health insurance companies and employers from discriminating based on genetic information. GINA does not apply to life insurance, disability insurance, or long-term care insurance. These insurers can request genetic test results and adjust coverage or premiums accordingly. Kure Health does not share genetic data with any third party without explicit written consent. KureBioMap™ results are stored in HIPAA-compliant systems and never sold to data brokers or research databases.
The Signal-Based Medicine Approach to Genetic Information
Signal-Based Medicine™ treats genetic information as a blueprint for biological vulnerability, not a disease prediction. Your genes establish the efficiency of cellular processes: how effectively you produce energy, detoxify environmental chemicals, synthesize neurotransmitters, regulate inflammation, and repair DNA damage. These processes generate biological signals. Symptoms are the downstream consequence when signals become dysregulated.
Conventional medicine waits for disease onset before intervention. A patient with MTHFR 677 homozygosity and elevated homocysteine receives no intervention until cardiovascular disease manifests. Signal-Based Medicine intervenes at the biological signal level. The same patient receives methylated folate, B12, and B6 to normalize homocysteine before vascular damage occurs. The genetic variant is not a condition. It is a signal that requires upstream support.
Kure Health uses genetic testing to identify which biological signals require monitoring and which interventions prevent signal dysregulation from progressing to disease. This is precision prevention—not managing disease after onset, not waiting for symptoms to become severe enough for pharmaceutical intervention. Addressing biological dysfunction at the signal level when intervention is most effective and least invasive.
Your genes do not determine your health outcome. They determine which environmental inputs matter most for your biology. Genetic testing becomes clinically valuable when it answers this question: which specific interventions does my unique biology require to maintain optimal function? KureBioMap™ Signal System Mapping provides that answer.
About the Author
Kenton Gray is a Marine veteran, Signal-Based Medicine pioneer, and Founder of Kure Health. He established Kure Health to address root causes of chronic dysfunction through genomic analysis, signal assessment, and mechanism-targeted intervention.
